Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable [clinical] result” cheered Wall Street, ...

Sana Biotechnology Inc.'s stock soared over 200% on Wednesday, on track to mark its best day on record, amid trading volumes ...

Samantha Semenkow, an analyst from Citi, maintained the Buy rating on Sana Biotechnology (SANA – Research Report). The associated price target ...

After years of controversy, stem cells are on the cusp of cures for conditions like epilepsy and type 1 diabetes.

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with ...

This study represents a crucial step in the ongoing search for effective T1D prevention methods. By showing that early ...

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

The updated guidelines from the American Diabetes Association emphasize the use of antibody-based screening for type 1 ...

Sana Biotechnology’s innovative approach to treating type 1 diabetes centers around its HIP-modified pancreatic islet cell transplant. In the context of type 1 diabetes, the body’s immune system ...

Surreal” is how Kelsey Bascom describes her journey with Type 1 diabetes. That about covers how the actor and filmmaker went ...

Mount Sinai researchers discovered that harmine, a beta cell regenerative drug, may transform alpha cells into beta cells, ...

Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...